Overall, HDAC inhibitors show strong promise to treat some of the epigenetic bases of AML, although it is necessary to further examine combination therapies to ensure that the drugs do not interfere with each other’s ability to function. The gene discussed is HDAC9; the disease is acute myeloid leukemia.